Table 2. Overlap-Weighted Pairwise Association Between Types of Taxanes and Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.

EORTC QLQ-CIPN20 score	HR (95% CI)a	P value	HR (95% CI)b	P value	HR (95% CI)c	P value
Total Score
Paclitaxel vs nab-paclitaxel	0.68 (0.48-0.97)	.03	0.67 (0.47-0.96)	.03	0.59 (0.41-0.87)	.01
Docetaxel vs nab-paclitaxel	0.66 (0.46-0.95)	.02	0.66 (0.46-0.95)	.03	0.65 (0.45-0.94)	.02
Docetaxel vs paclitaxel	0.97 (0.69-1.36)	.85	0.98 (0.69-1.39)	.91	1.09 (0.75-1.59)	.65
Sensory scale
Paclitaxel vs nab-paclitaxel	0.49 (0.34-0.70)	<.001	0.48 (0.33-0.68)	<.001	0.44 (0.30-0.64)	<.001
Docetaxel vs nab-paclitaxel	0.54 (0.38-0.77)	<.001	0.53 (0.37-0.76)	<.001	0.52 (0.36-0.75)	<.001
Docetaxel vs paclitaxel	1.10 (0.76-1.58)	.61	1.12 (0.77-1.62)	.55	1.19 (0.81-1.77)	.38
Motor scale
Paclitaxel vs nab-paclitaxel	0.93 (0.65-1.34)	.71	0.91 (0.64-1.31)	.63	0.76 (0.52-1.11)	.15
Docetaxel vs nab-paclitaxel	0.71 (0.49-1.02)	.06	0.71 (0.49-1.03)	.07	0.69 (0.47-1.01)	.05
Docetaxel vs paclitaxel	0.75 (0.52-1.09)	.13	0.77 (0.53-1.12)	.17	0.91 (0.62-1.35)	.65
Autonomic scale
Paclitaxel vs nab-paclitaxel	1.10 (0.76-1.60)	.61	1.08 (0.74-1.57)	.68	1.00 (0.68-1.49)	.98
Docetaxel vs nab-paclitaxel	0.85 (0.58-1.25)	.41	0.86 (0.58-1.26)	.43	0.88 (0.59-1.30)	.52
Docetaxel vs paclitaxel	0.77 (0.53-1.13)	.18	0.79 (0.54-1.16)	.23	0.88 (0.58-1.32)	.53

Abbreviations: EORTC QLQ-CIPN20, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire: Chemotherapy-Induced Peripheral Neuropathy 20-item; HR, hazard ratio.

^a Univariate model only include types of taxanes.

^b Multivariable models accounted for baseline characteristics, including patient age, ethnicity, body mass index, diabetes, history of peripheral neuropathy, treatment stage, and chemotherapy regimens.

^c Model further adjusted for treatment cycles and Ki-67.